Insititute for Clinical Pharmacodynamics: Publications

BY AUTHOR

Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R.
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009 Sep; 53(9):3847-54.

Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS.
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009 Aug; 22(4):279-85.

Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008 Sep; 62(1):99-101.

Tsuji BT, Yang JC, Forrest A, Kelchlin PA, Smith PF
In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus. J Antimicrob Chemother. 2008 Apr 9 [Epub ahead of print]

Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF.
Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother. 2008 Apr;52(4):1533-7. Epub 2008 Feb 19.

Ma Q, Forrest A, Rosenkranz SL, Para MF, Yarasheski KE, Reichman RC, Morse GD; ACTG A5043 Protocol Team, DAIDS, NIH.
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos. 2008 Mar;29(2):91-101.

Marraffa J, Forrest A, Grant W, Stork C, McMartin K, Howland MA.
Oral administration of fomepizole produces similar blood levels as identical intravenous dose. Clin Toxicol (Phila). 2008 Mar;46(3):181-6.

Gengo FM, Rainka M, Robson M, Gengo MF, Forrest A, Hourihane M, Bates V.
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol. 2008 Mar;48(3):335-43. Epub 2008 Jan 25.

Moise PA, Smyth DS, El-Fawal N, Robinson DA, Holden PN, Forrest A, Sakoulas G.
Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2008 Jan;61(1):85-90. Epub 2007 Nov 27.

Yang JC, Tsuji BT, Forrest A.
Optimizing use of quinolones in the critically ill. Semin Respir Crit Care Med. 2007 Dec;28(6):586-95.

Ambrose PG, Forrest A, Craig WA, Rubino CM, Bhavnani SM, Drusano GL, Heine HS.
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrob Agents Chemother. 2007 Dec;51(12):4351-5. Epub 2007 Sep 17.

Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD.
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. Am J Addict. 2007 Nov-Dec;16(6):488-94.

Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-87. Epub 2007 Jul 16.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD.
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit. 2007 Oct;29(5):560-5.

Ma Q, Brazeau D, Forrest A, Morse GD.
Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics. 2007 Sep;8(9):1169-78.

Donovan JL, Schroeder WS, Tran MT, Foster K, Forrest A, Lee TB, Gandhi PJ.
Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists. J Manag Care Pharm. 2007 Sep;13(7):598-606.

Moise PA, Sakoulas G, Forrest A, Schentag JJ.
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2007 Jul;51(7):2582-6. Epub 2007 Apr 23.

Okusanya O, Forrest A, DiFrancesco R, Bilic S, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD; ACTG 5043 Protocol Team.
Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks. Antimicrob Agents Chemother. 2007 May;51(5):1822-6. Epub 2007 Feb 5.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD.
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007 Mar;8(3):227-35.

Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL.
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. 2007 Jan 1;44(1):79-86.

Smith PF, Tsuji B, Booker BM, Forrest A, Bajic S, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG.
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. Diagn Microbiol Infect Dis. 2006 Dec;56(4):379-86.

Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L.
Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother. 2006 Jul;50(7):2374-83.

Haas CE, Forrest A.
Pharmacokinetic and pharmacodynamic research in the intensive care unit: an unmet need. Crit Care Med. 2006 Jun;34(6):1831-3.

Qazi YA, Forrest A, Tornatore K, Venuto RC.
The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant. 2006 May-Jun;20(3):313-7.

Covarrubias VG, Lakhman SS, Forrest A, Relling MV, Blanco JG.
Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett. 2006 Feb 11.

Bhasi K, Forrest A, Ramanathan M.
Application of SPLINDID, a semiparametric, model-based method for pharmacogenomic modeling of mRNA dynamics. Pharm Res. 2006 Apr;23(4):663-9.

Hammel JP, Bhavnani SM, Jones RN, Forrest A, Ambrose PG.
Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables. Antimicrob Agents Chemother. 2006 Jan;50(1):62-7.

Haas CE, Nelsen JL, Raghavendran K, Mihalko W, Beres J, Ma Q, Forrest A.
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. Trauma 2005 Dec;59(6):1336-43; discussion 1343-4.

Bhasi K, Forrest A, Ramanathan M.
SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles. Bioinformatics 2005 Oct 15;21(20):3873-9.

Zelenitsky S, Ariano R, Harding G, Forrest A.
Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother. 2005 Oct;49(10):4009-14.

Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, Catanzaro LM, Forrest A, Morse GD.
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):473-85.

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD.
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2005 Aug;49(8):3558-61.

Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN, Ambrose PG.
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother. 2005 May;49(5):1775-81.

Smith PF, Dicenzo R, Forrest A, Shelton M, Friedland G, Para M, Pollard R, Fischl M, DiFrancesco R, Morse GD.
Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals. Clin Pharmacokinet. 2005;44(1):99-109.

Overholser BR, Kays MB, Forrest A, Sowinski KM.
Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol. 2004 Sep;44(9):1012-22.

Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM.
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004 Jun;42(6):2398-402.

Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ.
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother. 2004 Jun;48(6):2061-8.

Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC J.
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis. 2004 Jun 15;38(12):1700-5.

Broder KW, Moise PA, Schultz RO, Forrest A, Schentag JJ.
Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Ann Plast Surg. 2004 Apr;52(4):385-90.

DiCenzo R, Forrest A, Fischl MA, Collier A, Feinberg J, Ribaudo H, DiFrancecso R, Morse GD.
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2004 Mar;48(3):918-23.

Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ.
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925-42.

Bhavnani SM, Callen WA, Forrest A, Gilliland KK, Collins DA, Paladino JA, Schentag JJ.
Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health Syst Pharm. 2003 Oct 1;60(19):1962-70.

Schentag JJ, Meagher AK, Forrest A.
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother. 2003 Oct;37(10):1478-88.

Paladino JA, Sunderlin JL, Forrest A, Schentag JJ.
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2003 Sep;52(3):457-63.

Schentag JJ, Meagher AK, Forrest A.
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models. Ann Pharmacother. 2003 Sep;37(9):1287-98.

Bhavnani SM, Hammel JP, Forrest A, Jones RN, Ambrose PG.
Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. Clin Infect Dis. 2003 Aug 1;37(3):344-50.

DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G.
Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy. 2003 Jul;23(7):866-70.

DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD.
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003 Jun;47(6):1929-35.

Smith PF, Birmingham MC, Noskin GA, Meagher AK, Forrest A, Rayner CR, Schentag JJ.
Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann. Oncol. 2003 May;14(5):795-801.

DiCenzo R, Forrest A, Slish JC, Cole C, Guillet R.
A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy. 2003 May;23(5):585-91.

Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ.
Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003 Feb;47(2):548-53.

Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ.
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411-23.

Moise PA, Forrest A, Birmingham MC, Schentag JJ.
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother. 2002 Dec;50(6):1017-26.

Paladino JA, Gudgel LD, Forrest A, Niederman MS.
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest. 2002 Oct;122(4):1271-9.

Smith PF, Forrest A, Adams JM, Ballow CH.
Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racemate. J Clin Pharmacol. 2002 Jun;42(6):658-61.

Miyazawa Y, Paul Starkey L, Forrest A, Schentag JJ, Kamimura H, Swarz H, Ito Y.
Effects of the concomitant administration of tamsulosin (0.8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin) in normal healthy subjects: a placebo-controlled evaluation. J Clin Pharm Ther. 2002 Feb;27(1):13-9.

Miyazawa Y, Starkey LP, Forrest A, Schentag JJ, Kamimura H, Swarz H, Ito Y
Effects of the concomitant administration of tamsulosin (0.8 mg/day) on the pharmacokinetic and safety profile of theophylline (5 mg/kg): a placebo-controlled evaluation. J Int Med Res. 2002 Jan-Feb;30(1):34-43.

Tornatore KM, Garey KW, Saigal N, Reed K, Murray B, Ingalls E, DiFrancesco R, Forrest A, Morse G, Venuto R.
Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. Clin Transplant. 2001 Oct;15(5):297-308.

Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ.
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther. 2001 Aug;23(8):1231-44.

Scott JD, Forrest A, Feuerstein S, Fitzpatrick P, Schentag JJ.
Factors associated with postoperative infection. Infect Control Hosp Epidemiol. 2001 Jun;22(6):347-51.

Allen K, Golden LH, Izzo JL Jr, Ching MI, Forrest A, Niles CR, Niswander PR, Barlow JC.
Normalization of hypertensive responses during ambulatory surgical stress by perioperative music. Psychosom Med. 2001 May-Jun;63(3):487-92.

Meinl B, Hyatt JM, Forrest A, Chodosh S, Schentag JJ.
Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone. Int J Antimicrob Agents. 2000 Nov;16(3):273-80.

Paladino JA, Fong LD, Forrest A, Ramphal R.
Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients. Pharmacoeconomics. 2000 Oct;18(4):369-81.

Smith PF, Forrest A, Ballow CH, Martin DE, Proulx L.
Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males. Antimicrob Agents Chemother. 2000 Oct;44(10):2816-23.

Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ.
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm. 2000 Oct 15;57 Suppl 2:S4-9.

Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL J.
Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. Am J Cardiol. 2000 Sep 1;86(5):519-23.

Smith PF, Forrest A, Ballow CH, Martin DE, Proulx L.
Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans. Antimicrob Agents Chemother. 2000 Jun;44(6):1609-15.

Tran JQ, Ballow CH, Forrest A, Hyatt JM, Sands MF, Peloquin CA, Schentag JJ.
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. J Antimicrob Chemother. 2000 Mar;45:9-17.

Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH.
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000 Mar;36(3):145-58.